person · Reporting owner
HENDERSON MICHAEL THOMAS
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Chief Business Officer | December 15, 2020 | December 17, 2020 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date December 15, 2020 · Filed December 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-04-01 | Direct | 4,456 |
Reported balance
After 2020-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-15 · Grant · Acquired 4,456 · Balance 4,456 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F2: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-07-20 | Direct | 3,137 |
Reported balance
After 2020-12-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-15 · Grant · Acquired 3,137 · Balance 3,137 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.80 · Expires 2030-09-29 | Direct | 2,199 |
Reported balance
After 2020-12-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-15 · Grant · Acquired 2,199 · Balance 2,199 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.
F2: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
F3: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
F4: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
Spyre Therapeutics, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,606 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Sale · Disposed 20,000 · Balance 68,606 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARYA Sciences Acquisition Corp IV
Report date July 31, 2024 · Filed August 01, 2024
Section 16 reporting ended · disclosed 2024-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-31 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.
Apogee Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Disposition to issuer · Disposed 920,941 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Disposition to issuer · Disposed 387,012 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 357,036 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 253,016 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2020 Filed Sep 22, 2020 23:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 5,099 | $0.28 | $1,427.72 |
DisclosureSEC source: 0000899243-20-025961 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 4,901 | $0.16 | $784.16 |
DisclosureSEC source: 0000899243-20-025961 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0000899243-20-024078 · doc4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,487 Underlying: Common Stock · 10,000 shares Expires 2028-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,978 | $29.58 | $147,251.73 |
DisclosureSEC source: 0000899243-20-024078 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $29.33 to $29.80 per share. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,022 | $27.89 | $140,082.66 |
DisclosureSEC source: 0000899243-20-024078 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,729 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $27.54 to $28.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 10,000 | $0.16 | $1,600.00 |
DisclosureSEC source: 0000899243-20-024078 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 12,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022794 · doc4.xml · derivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,188 Underlying: Common Stock · 12,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F4 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 5,460 | $28.53 | $155,773.80 |
DisclosureSEC source: 0000899243-20-022794 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 12,812 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 12,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022794 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 106 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0000899243-20-021505 · doc4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,487 Underlying: Common Stock · 10,000 shares Expires 2028-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,103 | $28.11 | $31,005.66 |
DisclosureSEC source: 0000899243-20-021505 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,293 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $27.98 to $28.22 per share Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,897 | $27.28 | $242,735.07 |
DisclosureSEC source: 0000899243-20-021505 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,396 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $26.85 to $27.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 10,000 | $0.16 | $1,600.00 |
DisclosureSEC source: 0000899243-20-021505 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0000899243-20-018483 · doc4.xml · derivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,487 Underlying: Common Stock · 10,000 shares Expires 2028-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 200 | $32.67 | $6,533.00 |
DisclosureSEC source: 0000899243-20-018483 · doc4.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,293 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F4 · price: Represents the weighted average sale price of the shares sold from $32.56 to $32.77 per share. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,632 | $31.77 | $83,628.90 |
DisclosureSEC source: 0000899243-20-018483 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,493 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $31.28 to $32.17 per share. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,168 | $30.63 | $219,539.35 |
DisclosureSEC source: 0000899243-20-018483 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,125 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $30.13 to $31.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 10,000 | $0.16 | $1,600.00 |
DisclosureSEC source: 0000899243-20-018483 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 100 | $30.05 | $3,005.25 |
DisclosureSEC source: 0000899243-20-015957 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,293 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 506 | $30.00 | $15,180.00 |
DisclosureSEC source: 0000899243-20-015957 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,393 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. Read SEC document |
| June 03, 2020 Filed Dec 2, 2020 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 784 | $30.04 | $23,548.54 |
DisclosureSEC source: 0000899243-20-032503 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,399 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.00 to $30.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 500 | $29.79 | $14,896.00 |
DisclosureSEC source: 0000899243-20-015042 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,683 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $29.68 to $29.86 per share. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,085 | $29.26 | $61,015.65 |
DisclosureSEC source: 0000899243-20-015042 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,183 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $28.65 to $29.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| May 26, 2020 Filed May 27, 2020 20:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,365 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000899243-20-014325 · doc4.xml · derivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,365 shares Expires 2029-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 27, 2020 20:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 18,365 | $1.05 | $19,283.25 |
DisclosureSEC source: 0000899243-20-014325 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 18,365 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 11 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,365 Underlying: Common Stock · 18,365 shares Expires 2029-12-17 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 19,271 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 10 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,271 Underlying: Common Stock · 19,271 shares Expires 2028-06-24 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F8 · derivative.exercise_date: 10,840 shares subject to the stock option were vested as of the date of acquisition, 402 shares shall vest on May 23, 2020, and 8,029 shares shall vest in monthly installments over the next 20 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 45,027 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 9 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,027 Underlying: Common Stock · 45,027 shares Expires 2029-09-24 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 13,932 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 8 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,932 Underlying: Common Stock · 13,932 shares Expires 2029-09-24 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 3,351 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 7 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,351 Underlying: Common Stock · 3,351 shares Expires 2029-06-10 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F7 · derivative.exercise_date: 2,030 shares shall vest and become exercisable on June 11, 2020, and 1,321 shares shall vest and become exercisable in monthly installments over the next 8 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 7,778 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 6 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,778 Underlying: Common Stock · 7,778 shares Expires 2029-05-28 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F6 · derivative.exercise_date: 5,654 shares subject to the stock option were vested as of the date of acquisition, 514 shares shall vest on May 29, 2020, and 1,610 shares shall vest in monthly installments over the next 4 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 39,487 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,487 Underlying: Common Stock · 39,487 shares Expires 2028-08-26 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F5 · derivative.exercise_date: 34,901 shares subject to the stock option were vested as of the date of acquisition, 1,246 shares shall vest May 22, 2020, and 3,340 shares shall vest in monthly installments over the next 3 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019 Underlying: Common Stock · 1,019 shares Expires 2028-05-07 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 7,335 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,335 Underlying: Common Stock · 7,335 shares Expires 2027-11-13 F4 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 205,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · derivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires not disclosed F2 · derivative.exercise_price: Restricted Stock Units are convertible to Common Stock on a 1 for 1 basis and have no expiration date. F3 · derivative.exercise_date: 6.25% of the units will vest on August 16, 2020 and an additional 6.25% of the units will vest in quarterly installments on the 16th day of February, May, August and November until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its Subsidiaries through each applicable vesting date. F2 · derivative.expiration_date: Restricted Stock Units are convertible to Common Stock on a 1 for 1 basis and have no expiration date. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:31 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 83,541 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013850 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,903 F1 · kind: The shares were acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer (each, a "Subsidiary" and collectively, the "Subsidiaries"). Read SEC document |
| May 05, 2020 Filed May 7, 2020 00:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,460 | $30.47 | $44,493.35 |
DisclosureSEC source: 0000899243-20-012196 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,362 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.13 to $30.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2020 Filed May 5, 2020 10:13 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,320 | $30.01 | $39,613.33 |
DisclosureSEC source: 0000899243-20-011988 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,822 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $30.00 to $30.06 per share. Read SEC document |
| May 01, 2020 Filed May 5, 2020 10:13 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 300 | $29.87 | $8,960.01 |
DisclosureSEC source: 0000899243-20-011988 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,142 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $29.82 to $29.93 per share. Read SEC document |
| May 01, 2020 Filed May 5, 2020 10:13 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,285 | $29.19 | $66,693.44 |
DisclosureSEC source: 0000899243-20-011988 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,442 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $28.76 to $29.74 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:13 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,100 | $27.56 | $30,313.03 |
DisclosureSEC source: 0000899243-20-010122 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,727 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $27.18 to $28.11 per share. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:13 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,441 | $26.51 | $38,198.60 |
DisclosureSEC source: 0000899243-20-010122 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,827 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $26.15 to $27.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:13 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 44 | $25.40 | $1,117.60 |
DisclosureSEC source: 0000899243-20-010122 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,268 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,400 | $32.89 | $46,047.12 |
DisclosureSEC source: 0000899243-20-006942 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,312 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $32.65 to $33.21 per share. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,575 | $32.20 | $82,918.09 |
DisclosureSEC source: 0000899243-20-006942 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,712 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $31.57 to $32.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,975 | $34.90 | $138,729.49 |
DisclosureSEC source: 0000899243-20-003297 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,287 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $34.63 to $35.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 02:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 26 | $33.00 | $858.01 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,262 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F7 · price: Represents the weighted average sale price of the shares sold from $32.91 to $33.14 per share. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 02:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 332 | $32.28 | $10,716.59 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,288 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F6 · price: Represents the weighted average sale price of the shares sold from $31.87 to $32.86 per share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 115 | $34.45 | $3,961.55 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,620 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $34.34 to $35.17 per share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,002 | $33.61 | $67,290.82 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,735 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $33.16 to $34.15 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.